TY  - JOUR
A1  - Solimando, Antonio Giovanni
A1  - Kalogirou, Charis
A1  - Krebs, Markus
T1  - Angiogenesis as therapeutic target in metastatic prostate cancer – narrowing the gap between bench and bedside
JF  - Frontiers in Immunology
N2  - Angiogenesis in metastatic castration-resistant prostate cancer (mCRPC) has been extensively investigated as a promising druggable biological process. Nonetheless, targeting angiogenesis has failed to impact overall survival (OS) in patients with mCRPC despite promising preclinical and early clinical data. This discrepancy prompted a literature review highlighting the tumor heterogeneity and biological context of Prostate Cancer (PCa). Narrowing the gap between the bench and bedside appears critical for developing novel therapeutic strategies. Searching clinicaltrials.gov for studies examining angiogenesis inhibition in patients with PCa resulted in n=20 trials with specific angiogenesis inhibitors currently recruiting (as of September 2021). Moreover, several other compounds with known anti-angiogenic properties – such as Metformin or Curcumin – are currently investigated. In general, angiogenesis-targeting strategies in PCa include biomarker-guided treatment stratification – as well as combinatorial approaches. Beyond established angiogenesis inhibitors, PCa therapies aiming at PSMA (Prostate Specific Membrane Antigen) hold the promise to have a substantial anti-angiogenic effect – due to PSMA´s abundant expression in tumor vasculature.
KW  - prostate adenocarcinoma
KW  - PCa
KW  - angiogenesis inhibitors
KW  - TKI
KW  - immunotherapy
KW  - tumor microenvironment
KW  - clinical trials
KW  - PSMA
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-263061
SN  - 1664-3224
VL  - 13
ER  -